Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Regen BioPharma (RGBP) Equity Ratio (2016 - 2025)

Regen BioPharma (RGBP) has disclosed Equity Ratio for 12 consecutive years, with 27.73 as the latest value for Q4 2025.

  • On a quarterly basis, Equity Ratio rose 6.55% to 27.73 in Q4 2025 year-over-year; TTM through Dec 2025 was 27.73, a 6.55% increase, with the full-year FY2025 number at 22.87, up 29.38% from a year prior.
  • Equity Ratio was 27.73 for Q4 2025 at Regen BioPharma, down from 22.87 in the prior quarter.
  • In the past five years, Equity Ratio ranged from a high of 8.66 in Q2 2021 to a low of 121.66 in Q1 2022.
  • A 5-year average of 29.71 and a median of 25.3 in 2025 define the central range for Equity Ratio.
  • Biggest YoY gain for Equity Ratio was 90.34% in 2021; the steepest drop was 984.22% in 2021.
  • Regen BioPharma's Equity Ratio stood at 13.27 in 2021, then rose by 11.1% to 11.8 in 2022, then plummeted by 178.54% to 32.86 in 2023, then increased by 9.7% to 29.67 in 2024, then increased by 6.55% to 27.73 in 2025.
  • Per Business Quant, the three most recent readings for RGBP's Equity Ratio are 27.73 (Q4 2025), 22.87 (Q3 2025), and 29.55 (Q2 2025).